SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    C.-H. Liu, C.-J. Liu, C.-F. Huang, J.-W. Lin, C.-Y. Dai, C.-C. Liang, J.-F. Huang, P.-H. Hung, H.-B. Tsai, M.-K. Tsai, C.-Y. Lee, S.-I. Chen, S.-S. Yang, T.-H. Su, H.-C. Yang, P.-J. Chen, D.-S. Chen, W.-L. Chuang, M.-L. Yu, J.-H. Kao, Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial, Gut, 2015, 64, 2, 303

    CrossRef

  2. 2
    A. Rivero-Juarez, L. F. Lopez-Cortes, A. Camacho, J. A. Mira, F. Tellez, M. Marquez, D. Merino, J. A. Pineda, A. Rivero, A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate, Clinical Infectious Diseases, 2014, 58, 1, 130

    CrossRef

  3. 3
    KASL clinical practice guidelines: Management of Hepatitis C, Clinical and Molecular Hepatology, 2014, 20, 2, 89

    CrossRef

  4. You have free access to this content4
    A. F. Stättermayer, R. Strassl, A. Maieron, K. Rutter, R. Stauber, M. Strasser, S. Beinhardt, C. Datz, T.-M. Scherzer, P. Steindl-Munda, M. Gschwantler, M. Trauner, H. Hofer, P. Ferenci, Polymorphisms of interferon-λ4 and IL28B – effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2014, 39, 1
  5. 5
    Yuki Wada, Hideyuki Tamai, Akiko Uno, Akira Kawashima, Naoki Shingaki, Yoshiyuki Mori, Kosaku Moribata, Kaori Miyata, Katsuhiko Higashi, Hisanobu Deguchi, Kazuki Ueda, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masao Ichinose, Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks, Hepatology Research, 2014, 44, 2
  6. You have free access to this content6
    Eleonora Grassi, Alessio Aghemo, How to optimize HCV therapy in genotype 2 patients, Liver International, 2013, 33,
  7. 7
    Tatsuya Minami, Takahiro Kishikawa, Masaya Sato, Ryosuke Tateishi, Haruhiko Yoshida, Kazuhiko Koike, Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C, Journal of Gastroenterology, 2013, 48, 2, 254

    CrossRef

  8. 8
    Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history, Expert Review of Anti-infective Therapy, 2013, 11, 5, 459

    CrossRef

  9. 9
    Gian Maria Prati, Alessio Aghemo, Maria Grazia Rumi, Roberta D’Ambrosio, Stella De Nicola, Maria Francesca Donato, Elisabetta Degasperi, Massimo Colombo, Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis, Journal of Hepatology, 2012, 56, 2, 341

    CrossRef

  10. 10
    Dong Hyun Park, Sang Uk Lee, Jin Seok Yu, Jun Seop Lee, Hye Jung Kwon, The Combination Therapy with Peg-interferon Alfa and Ribavirin for Chronic Hepatitis C in Korea as an Initial Treatment, Kosin Medical Journal, 2012, 27, 2, 111

    CrossRef

  11. 11
    Baptiste Hervier, Laurent Arnaud, Frederic Charlotte, Bertrand Wechsler, Jean Charles Piette, Zahir Amoura, Julien Haroche, Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α, Seminars in Arthritis and Rheumatism, 2012, 41, 6, 907

    CrossRef

  12. 12
    Alessandra Mangia, Leonardo Mottola, Treatment of Non-Genotype 1 Hepatitis C Virus Patients, Current Gastroenterology Reports, 2012, 14, 1, 87

    CrossRef

  13. 13
    Tatehiro Kagawa, Sei-ichiro Kojima, Koichi Shiraishi, Shinji Takashimizu, Naruhiko Nagata, Hirokazu Shiozawa, Yasuhiro Nishizaki, Akihiko Ikeda, Yoshihiro Tei, Kazuhiro Atsukawa, Jun-ichiro Kamochi, Mitsuru Wasada, Makoto Numata, Yoshitaka Arase, Shunji Hirose, Takuji Yamada, Yasuo Hata, Norihito Watanabe, Toshio Morizane, Tetsuya Mine, Weight-based high- and low-dose ribavirin in combination with peginterferon α-2b therapy for genotype 2 chronic hepatitis C: A randomized trial, Hepatology Research, 2012, 42, 4
  14. 14
    Thomas-Matthias Scherzer, Harald Hofer, Albert Friedrich Staettermayer, Karoline Rutter, Sandra Beinhardt, Petra Steindl-Munda, Heidrun Kerschner, Harald H. Kessler, Peter Ferenci, Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin, Journal of Hepatology, 2011, 54, 5, 866

    CrossRef

  15. 15
    Albert Friedrich Stättermayer, Rudolf Stauber, Harald Hofer, Karoline Rutter, Sandra Beinhardt, Thomas Matthias Scherzer, Kerstin Zinober, Christian Datz, Andreas Maieron, Emina Dulic–Lakovic, Harald H. Kessler, Petra Steindl–Munda, Michael Strasser, Christoph Krall, Peter Ferenci, Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C, Clinical Gastroenterology and Hepatology, 2011, 9, 4, 344

    CrossRef

  16. 16
    Elena Vezali, Alessio Aghemo, Massimo Colombo, Interferon in the treatment of chronic hepatitis C: a drug caught between past and future, Expert Opinion on Biological Therapy, 2011, 11, 3, 301

    CrossRef

  17. 17
    C. Pedersen, Å. Alsiö, M. Lagging, N. Langeland, M. Färkkilä, M. Rauning Buhl, K. Mørch, J. Westin, P. Sangfelt, G. Norkrans, P. Brehm Christensen, Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection, Journal of Viral Hepatitis, 2011, 18, 4
  18. 18
    Chalermrat Bunchorntavakul, K. Rajender Reddy, Ribavirin: How Does it Work and is it Still Needed?, Current Hepatitis Reports, 2011, 10, 3, 168

    CrossRef

  19. 19
    Andreas Maieron, Sigrid Metz-Gercek, Thomas-Matthias Scherzer, Hermann Laferl, Gabriele Fischer, Martin Bischof, Michael Gschwantler, Peter Ferenci, Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial, BMC Research Notes, 2011, 4, 1, 220

    CrossRef

  20. 20
    Takao Watanabe, Ichiro Konishi, Shuichiro Shigematsu, Kazuhiro Uesugi, Kouji Joko, Hirotaka Seike, Shinichi Okada, Hiroaki Miyaoka, Seiji Nakanishi, Masanori Abe, Bunzo Matsuura, Kojiro Michitaka, Norio Horiike, Yoichi Hiasa, Morikazu Onji, Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance, Hepatology Research, 2011, 41, 8
  21. 21
    Ahmad Amanzada, Armin Goralczyk, Federico Moriconi, Martina Blaschke, Inga-Marie Schaefer, David van Thiel, Sabine Mihm, Giuliano Ramadori, Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy, Digestive Diseases and Sciences, 2011, 56, 11, 3296

    CrossRef

  22. 22
    Andreas Maieron, Sigrid Metz-Gercek, Franz Hackl, Alexander Ziachehabi, Harri Fuchsteiner, Christoph Luger, Helmut Mittermayer, Rainer Schöfl, Antiviral treatment of chronic hepatitis C in clinical routine, Wiener klinische Wochenschrift, 2010, 122, 7-8, 237

    CrossRef

  23. 23
    Y. Inoue, N. Hiramatsu, T. Oze, T. Yakushijin, K. Mochizuki, H. Hagiwara, M. Oshita, E. Mita, H. Fukui, M. Inada, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, T. Miyagi, A. Hohsui, H. Ishida, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses, Journal of Viral Hepatitis, 2010, 17, 5
  24. 24
    Byung-Cheol Song, Is 24 Weeks of Peginterferon and Ribavirin Combination Therapy Sufficient for the Patients with Genotype 1 Chronic Hepatitis C?, The Korean Journal of Gastroenterology, 2010, 56, 1, 59

    CrossRef

  25. 25
    Mamta K Jain, Cindy Zoellner, Role of ribavirin in HCV treatment response: now and in the future, Expert Opinion on Pharmacotherapy, 2010, 11, 4, 673

    CrossRef

  26. 26
    Harald Hofer, Josef Donnerer, Kathrin Sator, Katharina Staufer, Thomas-Matthias Scherzer, Clemens Dejaco, Michael Sator, Harald Kessler, Peter Ferenci, Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy, Journal of Hepatology, 2010, 52, 6, 812

    CrossRef

  27. 27
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  28. 28
    Chung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu, A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration, Hepatology, 2009, 49, 4
  29. 29
    Erik De Clercq, Another ten stories in antiviral drug discovery (part C): “Old” and “new” antivirals, strategies, and perspectives, Medicinal Research Reviews, 2009, 29, 4
  30. 30
    S. Zeuzem, T. Berg, B. Moeller, H. Hinrichsen, S. Mauss, H. Wedemeyer, C. Sarrazin, D. Hueppe, E. Zehnter, M. P. Manns, Expert opinion on the treatment of patients with chronic hepatitis C, Journal of Viral Hepatitis, 2009, 16, 2
  31. 31
    Nina Ebner, Christian Wanner, Bernadette Winklbaur, Christian Matzenauer, Crispa Aeschbach Jachmann, Kenneth Thau, Gabriele Fischer, HEPATITIS C AND ADDICTION: Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients, Addiction Biology, 2009, 14, 2
  32. 32
    Peter Ferenci, Reply:, Hepatology, 2009, 49, 2
  33. 33
    Peter Ferenci, Reply:, Hepatology, 2009, 49, 4
  34. 34
    N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin, Journal of Viral Hepatitis, 2009, 16, 8
  35. 35
    Susan J. Keam, Risto S. Cvetković, Spotlight on Peginterferon-α-2a (40 kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection†, BioDrugs, 2009, 23, 1, 63

    CrossRef

  36. 36
    Alessio Aghemo, Maria Grazia Rumi, Gian Maria Prati, Massimo Colombo, The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?, Hepatology, 2009, 49, 2
  37. 37
    Fred Poordad, Nancy Reau, Viral-guided hepatitis C therapy, Current Hepatitis Reports, 2009, 8, 2, 66

    CrossRef

  38. 38
    Ine-Mari Bornman, Zobair M. Younossi, CAN THE DOSE OF RIBAVIRIN BE REDUCED FOR PATIENTS INFECTED WITH HEPATITIS C, GENOTYPES 2 AND 3?, Evidence-Based Gastroenterology, 2008, 9, 4, 71

    CrossRef

  39. 39
    Alessandra Mangia, Angelo Andriulli, Reply:, Hepatology, 2008, 48, 3
  40. 40
    Maribel Rodríguez-Torres, Carlos F. Ríos-Bedoya, Grisell Ortiz-Lasanta, Dagmary Purcell-Arevalo, Acisclo Marxuach-Cuétara, Josselyn Jiménez-Rivera, Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks, Journal of Medical Virology, 2008, 80, 9
  41. 41
    Stella Martínez, Jose María Sánchez-Tapias, Xavier Forns, Genotypes 2 and 3 Relapse and Non-Response,
  42. 42
    Kenneth Yan, Amany Zekry, Standard Therapy for Genotypes 2/3,